Xeris Biopharma (NASDAQ:XERS) Shares Up 6.8% – Time to Buy?

Posted by Brenda Bartman on Oct 21st, 2026

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) shot up 6.8% during mid-day trading on Monday. The company traded as high as $11.05 and last traded at $11.0160. 1,152,083 shares traded hands during mid-day trading, a decline of 43% from the average daily volume of 2,007,346 shares. The stock had previously closed at $10.31.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Wall Street Zen raised Xeris Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Leerink Partners raised their target price on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a report on Thursday, September 10th. Finally, Barclays lifted their price target on shares of Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 6th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $13.20.

Check Out Our Latest Report on Xeris Biopharma

Xeris Biopharma Price Performance

The stock has a fifty day moving average of $8.99 and a 200-day moving average of $7.72. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. The stock has a market capitalization of $2.03 billion, a price-to-earnings ratio of -101.18 and a beta of 0.53.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. The company had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. On average, equities research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Insider Buying and Selling

In other Xeris Biopharma news, insider Steven Pieper sold 5,000 shares of the firm’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $9.41, for a total transaction of $47,050.00. Following the transaction, the insider owned 1,351,053 shares of the company’s stock, valued at approximately $12,713,408.73. This trade represents a 0.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,666 shares of the business’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $9.41, for a total value of $156,827.06. Following the completion of the sale, the insider directly owned 1,111,130 shares of the company’s stock, valued at $10,455,733.30. The trade was a 1.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 134,998 shares of company stock worth $1,202,666 in the last ninety days. 4.35% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Xeris Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XERS. Allworth Financial LP lifted its position in Xeris Biopharma by 86.4% during the 2nd quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock worth $34,000 after acquiring an additional 2,000 shares during the period. AlphaCentric Advisors LLC grew its stake in shares of Xeris Biopharma by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock valued at $266,000 after purchasing an additional 2,494 shares during the last quarter. GK Wealth Management LLC acquired a new position in shares of Xeris Biopharma in the third quarter valued at approximately $32,000. KBC Group NV acquired a new position in shares of Xeris Biopharma in the first quarter valued at approximately $27,000. Finally, Royal Bank of Canada increased its holdings in shares of Xeris Biopharma by 12.9% in the first quarter. Royal Bank of Canada now owns 43,610 shares of the company’s stock valued at $253,000 after purchasing an additional 4,974 shares during the period. Hedge funds and other institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

(Get Free Report)

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.